Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
BMC Neurosci (2013) 14:76
Fellow obesity leader Eli Lilly is also working on its own set of amylin programs, of which the mid-stage eloralintide is closest to the market
Archives of Pharmacal Research , 30(7), 834-839
[7] Farris, P.K
For type 2 diabetes management , NICE guideline NG28 recommends considering GLP-1 receptor agonists when: Triple therapy with metformin and two other oral medications is ineffective, not tolerated or contraindicated The patient has a body mass index (BMI) of 35 kg/m or higher (with lower thresholds for people from certain ethnic backgrounds), or lower BMI with specific clinical circumstances where weight loss would benefit other obesity-related comorbidities Insulin would have significant occupational implications GLP-1 therapy should only be continued beyond six months if there has been a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0 percentage point) and weight loss of at least 3% of initial body weight
US$ 28.73
US$ 26.82
US$ 24.81
US$ 27.36
US$ 24.12
US$ 20.90
US$ 25.99
US$ 27.81
